Sensus Healthcare Bets on 2026 Reimbursement Rebound
Sensus Healthcare, Inc. ((SRTS)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sensus Healthcare’s latest earnings call struck a cautious tone as steep 2025 revenue declines and a swing to losses clashed with management’s optimism about a looming reimbursement windfall and international growth. Executives framed 2026 as a transition year toward renewed profitability, but uncertainty around a key lost customer kept investor sentiment measured rather than euphoric.
New CPT Codes Set Up a Reimbursement Inflection
CMS granted exclusive CPT codes for superficial and image-guided SRT effective January 2026, which management said should boost per‑fraction reimbursements by roughly 300%. This move creates clearer economics for nonmelanoma skin cancer treatment and underpins Sensus’s thesis that utilization and system demand will inflect higher next year.
Balance Sheet Strength Buys Time for the Turnaround
The company closed 2025 with $22.1 million in cash and cash equivalents, unchanged year over year, and no borrowings under its revolver. This debt‑free position gives Sensus room to fund commercialization, R&D, and inventory without immediate pressure to raise capital even as the income statement deteriorates.
FDA Fair Deal Program Shows Accelerating Adoption
Sensus highlighted its FDA fair deal program as proof of growing clinical traction, exiting 2025 with 18 active sites and 10 more pending activation. Treatments under the program rose more than eightfold and patients treated climbed over 250%, signaling expanding physician comfort and validating the technology’s value proposition.
Q4 Shipments Underscore International Momentum
The company shipped 14 systems in Q4, including eight in the U.S. and six internationally with contributions from China. Management called out attractive margins and sustained momentum in China, Taiwan, and South Korea, and noted that expected Brazil clearance in 2026 should further broaden the global footprint.
Commercial Scaling and Sales Hiring to Capture Demand
With reimbursement clarity on the horizon, Sensus is preparing to scale its commercial engine and accelerate market education. The company has already added one sales representative and plans to hire three to five more in 2026 to improve lead conversion and drive system placements as utilization ramps.
Inventory Build Aims to Meet Anticipated Uptick
Inventories climbed to $14.6 million from $10.1 million, a roughly 45% increase that management framed as a proactive build. Sensus says this stock positions it to respond quickly to expected demand once new CPT codes take effect and commercial efforts deepen.
Product Pipeline and Regulatory Advances
R&D spending jumped to $7.8 million from $4.2 million as Sensus pushed next‑generation systems and previewed its Sentinel 2.0 initiative. The company also secured MDSAP certification, which broadens access to multiple international markets and supports its strategy of diversifying growth beyond the U.S.
Revenue Collapse Highlights Near-Term Pain
Q4 2025 revenue plunged to $4.9 million from $31.0 million a year earlier, an 84% year‑over‑year decline driven mainly by fewer units shipped and weaker sales to its largest customer. The full year told a similar story, with revenue down 34% to $27.5 million from $41.8 million in 2024 as unit volumes fell.
Profitability Reverses Amid EBITDA and Margin Pressure
Sensus swung from a $6.6 million profit in 2024 to a $7.7 million net loss in 2025, with adjusted EBITDA turning from positive $8.7 million to negative $9.6 million. Gross margins compressed sharply, falling to 38.8% in Q4 and 43.3% for the year as lower volumes, higher service costs, and program expenses weighed on profitability.
Operating Costs Rise as Company Invests Through the Downturn
Operating expenses rose across the board, with R&D up nearly 86%, selling and marketing up 30%, and G&A up about 11%. These investments deepened 2025 operating losses but reflect management’s decision to spend through the downturn to position for future growth and product differentiation.
Customer Concentration and Inventory Heighten Risk
Performance was hit hard by reduced orders from Sensus’s historically largest customer, and 2026 guidance explicitly excludes any contribution from that account. At the same time, the sizable inventory build could pressure working capital and margins if adoption under new reimbursement takes longer than management expects.
Guidance Points to Sequential Improvement in 2026
Management guided that Q1 2026 system shipments should exceed Q4’s 14 units and that Q1 revenue should top the prior quarter’s $4.9 million, even without the largest customer. The company reiterated its goal of achieving full‑year profitability in 2026, leaning on new CPT codes, expanded sales capacity, a cash‑rich balance sheet, and growing international demand to drive higher utilization and earnings.
Sensus Healthcare’s earnings call laid out a stark contrast between a punishing 2025 and a potentially brighter 2026 built on reimbursement catalysts and global expansion. For investors, the story now hinges on whether management can convert regulatory wins and a strong balance sheet into sustained demand fast enough to offset customer losses and justify the company’s heavier investment load.
Disclaimer & DisclosureReport an Issue
